Lexeo Therapeutics (LXEO) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $300 million of its securities via one or more offerings.
The registration covers common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts, and units, according to the filing.
The company said it will outline how it plans to use the proceeds from the sale of securities in a prospectus supplement.
Price: 7.12, Change: -0.01, Percent Change: -0.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.